<SEC-DOCUMENT>0001193125-26-084309.txt : 20260302
<SEC-HEADER>0001193125-26-084309.hdr.sgml : 20260302
<ACCEPTANCE-DATETIME>20260302081628
ACCESSION NUMBER:		0001193125-26-084309
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20260302
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260302
DATE AS OF CHANGE:		20260302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intellia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001652130
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				364785571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37766
		FILM NUMBER:		26703583

	BUSINESS ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-6200

	MAIL ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d101756d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ntla="http://intelliatx.com/20260302" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-331">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-03-02_to_2026-03-02">0001652130</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ntla-20260302.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-03-02_to_2026-03-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001652130</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-03-02</xbrli:startDate> <xbrli:endDate>2026-03-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-342">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt:datemonthdayyearen" id="ixv-343">March 2, 2026</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-344">INTELLIA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:stateprovnameen" id="ixv-345">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-346">001-37766</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-347">36-4785571</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-348">40 Erie Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-349">Suite 130</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-350">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:stateprovnameen" id="ixv-351">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-352">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-353">(857)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-354">285-6200</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:boolballotbox" id="ixv-356">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:boolballotbox" id="ixv-357">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:boolballotbox" id="ixv-358">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-359">Common Stock (Par Value $0.0001)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-360">NTLA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:exchnameen" id="ixv-361">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-03-02_to_2026-03-02" format="ixt-sec:boolballotbox" id="ixv-362">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. (the &#8220;Company&#8221;) previously entered into an Open Market Sale Agreement, dated March&#160;4, 2022, and amended on February&#160;23, 2024 (as amended, the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $750,000,000, through Jefferies as its sales agent. Pursuant to the Sales Agreement, the sale and issuance of the shares under the Sales Agreement were originally made pursuant to a registration statement on Form <span style="white-space:nowrap">S-3ASR</span> (File <span style="white-space:nowrap">No.&#160;333-251022)</span> filed on November&#160;30, 2020 (the &#8220;Prior Prospectus&#8221;) and subsequently pursuant to an effective registration statement on Form <span style="white-space:nowrap">S-3ASR</span> (File <span style="white-space:nowrap">No.&#160;333-275740)</span> filed on November&#160;24, 2023 (the &#8220;Existing Registration Statement&#8221;) and a prospectus supplement filed on February&#160;23, 2024 (together with the Existing Registration Statement, the &#8220;Existing Prospectus&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering program from $750,000,000 to $1,035,316,650. As of the date of this Current Report on Form <span style="white-space:nowrap">8-K,</span> we have sold approximately $635,316,650 of shares of Common Stock under the Sales Agreement pursuant to the Prior Prospectus and the Existing Prospectus, including any supplements thereto that we have filed from time to time. On March&#160;2, 2026, we will file a prospectus supplement (the &#8220;New Prospectus&#8221;) to our Existing Prospectus, which will update the Existing Prospectus. The New Prospectus covers the offer and sale of up to $400,000,000 of shares of Common Stock (the &#8220;Additional Shares&#8221;) from time to time through Jefferies, acting as our sales agent, which is inclusive of the approximately $114,683,350 of shares of Common Stock that are not yet sold pursuant to the Existing Prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the amended Sales Agreement, sales of the shares of Common Stock under the Sales Agreement may be made by any method that is deemed an <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;at-the-market&#8221;</span></span> offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the Securities Act). We are not obligated to make any sales of shares of Common Stock under the amended Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the amended Sales Agreement, we or Jefferies may suspend the offering of shares being made through Jefferies, upon proper written notice to the other party. Jefferies will act as sales agent on a best efforts basis and has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Market to sell shares of Common Stock up to the number or amount specified in, and otherwise in accordance with the terms of, a placement notice delivered pursuant to the amended Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to pay Jefferies compensation for its services in cash up to 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the terms of the amended Sales Agreement. We also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies and/or its affiliates have provided, and may in the future provide various investment banking, commercial banking and other financial services to us and/or our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M of the Securities Exchange Act of 1934, as amended, Jefferies will not engage in any market making activities involving our common stock while the offering is ongoing under the prospectus and prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the Sales Agreement, as amended, is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which was filed as Exhibit 99.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed on March&#160;4, 2022, which is incorporated herein by reference, the amendment to the Sales Agreement, a copy of which was filed as Exhibit 99.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed on February&#160;23, 2024, which is incorporated herein by reference, and the amendment to the Sales Agreement, which is filed as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. Goodwin Procter LLP, our counsel, has issued a legal opinion relating to the Additional Shares being offered pursuant to the New Prospectus. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;2, 2026, Intellia issued a press release titled &#8220;Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in <span style="white-space:nowrap">ATTR-CM.&#8221;</span> A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information under this Item 7.01, including Exhibit 99.2 hereto, is being furnished herewith and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;2, 2026, Intellia announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has removed the clinical hold on the investigational new drug application (&#8220;IND&#8221;) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran <span style="white-space:nowrap">(&#8220;nex-z&#8221;)</span> for patients with transthyretin (&#8220;ATTR&#8221;) amyloidosis with cardiomyopathy <span style="white-space:nowrap">(&#8220;ATTR-CM&#8221;).</span> On October&#160;29, 2025, the FDA imposed a clinical hold on the INDs for the MAGNITUDE Phase 3 trial and the <span style="white-space:nowrap">MAGNITUDE-2</span> Phase 3 clinical trial of <span style="white-space:nowrap">nex-z</span> for patients with hereditary ATTR amyloidosis with polyneuropathy <span style="white-space:nowrap">(&#8220;ATTRv-PN&#8221;)</span> following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with <span style="white-space:nowrap">nex-z</span> in MAGNITUDE that met the trial&#8217;s protocol-defined pausing criteria. The Company has aligned with the FDA on mitigation measures&#160;for MAGNITUDE and <span style="white-space:nowrap">MAGNITUDE-2</span> that include enhanced monitoring of liver laboratory tests, guidance for short-term steroid treatment if elevated liver transaminases are observed in the initial period following dosing and the exclusion of patients with certain liver abnormalities. For MAGNITUDE, additional exclusion criteria are being incorporated for patients with a recent history of cardiovascular instability and those with ejection fraction &lt;25% at the time of screening. Intellia&#160;is engaged&#160;with clinical trial investigators, ethics committees,&#160;international&#160;regulatory&#160;authorities&#160;and other stakeholders&#160;to resume&#160;enrollment&#160;activities&#160;in&#160;MAGNITUDE <span style="white-space:nowrap">and&#160;MAGNITUDE-2.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;and&#160;certain</span> of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for <span style="white-space:nowrap">nex-z</span> for ATTR amyloidosis, including its MAGNITUDE Phase 3 study of <span style="white-space:nowrap">nex-z</span> for the treatment of <span style="white-space:nowrap">ATTR-CM</span> and its <span style="white-space:nowrap">MAGNITUDE-2</span> Phase 3 study of <span style="white-space:nowrap">nex-z</span> for the treatment of <span style="white-space:nowrap">ATTRv-PN;</span> and its ability to engage with clinical trial investigators, ethics committees, international regulatory authorities and other stakeholders to resume enrollment activities in&#160;MAGNITUDE <span style="white-space:nowrap">and&#160;MAGNITUDE-2.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this current report on Form <span style="white-space:nowrap">8-K</span> are based on management&#8217;s current expectations and beliefs regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: regulatory agencies&#8217; evaluation of regulatory filings and other information related to our product candidates, including <span style="white-space:nowrap">nex-z;</span> uncertainties related to the authorization, initiation and conduct of studies and other development requirements for Intellia&#8217;s product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia&#8217;s product candidates, including <span style="white-space:nowrap">nex-z,</span> will not be successfully developed and commercialized; risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#8217;s other product candidates; and risks related to Intellia&#8217;s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report on Form <span style="white-space:nowrap">10-K</span> and quarterly report on Form <span style="white-space:nowrap">10-Q,</span> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with the Securities and Exchange Commission. All information in this current report on Form <span style="white-space:nowrap">8-K</span> is as of the date of the report, and Intellia undertakes no duty to update this information unless required by law. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d101756dex51.htm">Opinion of Goodwin Procter LLP</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d101756dex991.htm">Amendment No.&#160;2 to the Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup>, dated as of March&#160;2, 2026, by and between Intellia Therapeutics, Inc. and Jefferies LLC</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d101756dex992.htm">Press Release dated March&#160;2, 2026, titled &#8220;Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in <span style="white-space:nowrap">ATTR-CM&#8221;</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Intellia Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;2, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Leonard</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: John M. Leonard</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: Chief Executive Officer and President</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d101756dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g101756g0301221517365.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;2, 2026&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">40 Erie Street, Suite 130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3ASR</FONT> (as amended or supplemented, the &#8220;Registration Statement&#8221;) filed on November&nbsp;24, 2023 with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to the
Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), relating to the registration of the offering by Intellia Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) of an indeterminate amount of any combination of
securities of the types specified therein. The Registration Statement became effective automatically on November&nbsp;24, 2023. Reference is made to our opinion letter dated November&nbsp;24, 2023 and included as Exhibit&nbsp;5.1 to the Registration
Statement. We are delivering this supplemental opinion letter in connection with the sales agreement prospectus (the &#8220;Prospectus&#8221;) contained in the Registration Statement. The Prospectus relates to the offering by the Company of up to
$400,000,000 in shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;) covered by the Registration Statement. The Shares are being offered and sold by the sales agent named in,
and pursuant to, the Open Market Sale Agreement, as amended, among the Company and such sales agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and
made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below,
on certificates of officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the opinion set forth below, we have assumed that the Shares are issued for a
price per share equal to or greater than the minimum price authorized by the Company&#8217;s board of directors prior to the date hereof (the &#8220;Minimum Price&#8221;) and that no event occurs that causes the number of authorized shares of Common
Stock available for issuance by the Company to be less than the number of then unissued Shares that may be issued for the Minimum Price. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;2, 2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the opinion set forth below, we refer to the following as &#8220;Future
Approval and Issuance&#8221;: (a) the approval by the Company&#8217;s board of directors (or a duly authorized committee of the board of directors) of the issuance of the Shares (the &#8220;Approval&#8221;) and (b)&nbsp;the issuance of the Shares in
accordance with the Approval and the receipt by the Company of the consideration (which shall not be less than the par value of such Shares) to be paid in accordance with the Approval.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon Future Approval and Issuance, will be
validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion letter and the opinions it contains shall be interpreted in accordance with
the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished to you for submission
to the Commission as an exhibit to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> relating to the Shares (the &#8220;Current Report&#8221;), which is incorporated by reference in the Registration Statement. We
hereby consent to the filing of this opinion letter as an exhibit to the Current Report and its incorporation by reference and the reference to our firm in that report. In giving our consent, we do not admit that we are in the category of persons
whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ GOODWIN PROCTER LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d101756dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENT<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;2, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;2
to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated as of March&nbsp;2, 2026, is entered into by and between Intellia Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;) and Jefferies LLC (the
&#8220;<B>Agent</B>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Sales Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Agent have entered into that certain Open Market Sale
Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated March&nbsp;4, 2022, as amended by that certain Amendment to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated as of February&nbsp;23,
2024 (the &#8220;<B>Sales Agreement</B>&#8221;), with respect to the issuance and sale of the Common Shares; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and
the Agent desire to amend the Sales Agreement as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, the Company and the
Agent hereby amend the Sales Agreement as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The preamble on page 1 of the Sales Agreement shall be amended such that the
reference to &#8220;$750,000,000&#8221; shall be &#8220;$1,035,316,650&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The first sentence of the Issuance Notice attached as
Exhibit A to the Sales Agreement is amended to add the words &#8220;and March&nbsp;2, 2026&#8221; immediately after &#8220;March 4, 2022, as amended on February&nbsp;23, 2024&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Schedule A of the Sales Agreement shall be amended such that the reference to &#8220;Glen Goddard (glen.goddard@intelliatx.com)&#8221;
shall be &#8220;Edward Dulac (Edward.dulac@intelliatx.com)&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Company shall file a Prospectus Supplement pursuant to Rule
424(b) of the Securities Act of 1933, as amended, reflecting this Amendment within two Business Days of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This
Amendment shall be and is hereby incorporated in and forms a part of the Sales Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. This Amendment shall be effective as of the
date first above written. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This Amendment may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Amendment by one party to the other may be made by facsimile or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. This Amendment shall, by this express agreement of the parties, be governed by, and construed and enforced in accordance with, the laws of
the State of New York, without regard to the conflicts of law provisions of the laws of the State of New York. The Company and the Agent each hereby consents to the application of New York civil law to the construction, interpretation and
enforcement of this Amendment, and to the application of New York civil law to the procedural aspects of any suit, action or proceeding relation thereto, including but not limited to legal process, execution of judgments and other legal remedies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Except as set forth herein, the Sales Agreement shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Pages Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INTELLIA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Leonard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: John M. Leonard</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer and President</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Magarro</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Michael Magarro</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d101756dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g101756dsp19a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g101756dsp19b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellia Therapeutics Announces FDA Lift of Clinical Hold on </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAGNITUDE Phase 3 Clinical Trial in <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., March 2, 2026 &#8211; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine
leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of
nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy <FONT STYLE="white-space:nowrap">(ATTR-CM).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;We
are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate nex-z in a broad
<FONT STYLE="white-space:nowrap">ATTR-CM</FONT> population,&#8221; said Intellia President and Chief Executive Officer John Leonard, M.D. &#8220;With the resolution in January of the clinical hold on our
<FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials. We appreciate the FDA&#8217;s responsiveness throughout
this process and thank the many investigators and patients who are participating in these trials.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical holds on the INDs for MAGNITUDE and
<FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> were imposed by the FDA on October&nbsp;29, 2025, following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met
the trial&#8217;s protocol-defined pausing criteria. The company has aligned with the FDA on mitigation measures for MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> that include enhanced monitoring of liver laboratory tests,
guidance for short-term steroid treatment if elevated liver transaminases are observed in the initial period following dosing and the exclusion of patients with certain liver abnormalities. For MAGNITUDE, additional exclusion criteria are being
incorporated for patients with a recent history of cardiovascular instability and those with ejection fraction &lt;25% at the time of screening. Intellia is engaged with clinical trial investigators, ethics committees, international regulatory
authorities and other stakeholders to resume enrollment activities in MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAGNITUDE is a
randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of nex-z in approximately 1,200 patients with <FONT STYLE="white-space:nowrap">ATTR-CM.</FONT> The primary endpoint of the trial is based on a composite measure of
cardiovascular-related events, including mortality. Adult patients with <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> are randomized 2:1 to receive a single 55 mg infusion of nex-z or placebo. For more information on MAGNITUDE (NCT06128629),
please visit&nbsp;<U>clinicaltrials.gov</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 1 of 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> is a randomized, double-blind, placebo-controlled trial
evaluating the efficacy and safety of nex-z in approximately 60 patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The primary endpoints of the study are a change in modified neuropathy impairment score and a change in serum
TTR levels. Adult patients with ATTRv-PN are randomized 1:1 to receive a single 55 mg infusion of nex-z or placebo. For more information on <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> (NCT06672237), please
visit&nbsp;<U>clinicaltrials.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;Nex-z</FONT></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Based on Nobel <FONT STYLE="white-space:nowrap">Prize-winning</FONT> CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first <FONT
STYLE="white-space:nowrap">one-time</FONT> treatment for transthyretin (ATTR) amyloidosis with cardiomyopathy <FONT STYLE="white-space:nowrap">(ATTR-CM)</FONT> and/or hereditary ATTR with polyneuropathy (ATTRv-PN).
<FONT STYLE="white-space:nowrap">Nex-z</FONT> is designed to inactivate the <I>TTR</I> gene that encodes for the transthyretin (TTR) protein and is being investigated in MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2,</FONT> Phase 3
clinical trials in <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and ATTRv-PN, respectively. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction.
<FONT STYLE="white-space:nowrap">Nex-z</FONT> has received an Orphan Drug and RMAT Designation from the U.S. Food and Drug Administration (FDA) and an Orphan Drug Designation (ODD) from the European Commission. Intellia leads development and
commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron Pharmaceuticals, Inc.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc.
(Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company&#8217;s mission is to transform the lives of people with severe diseases
by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at
<U>intelliatx.com</U> and follow us <U>@intelliatx</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#8220;forward-looking statements&#8221; of Intellia Therapeutics, Inc. (&#8220;Intellia&#8221; or the &#8220;Company&#8221;)
within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations regarding: the safety,
tolerability, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or &#8220;nex-z&#8221; (also known as NTLA-2001), including the ability to engage with clinical trial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 2 of 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigators, ethics committees, international regulatory authorities and other stakeholders to resume enrollment activities in its MAGNITUDE and
<FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> trials for nex-z in <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and ATTRv-PN, the ability to successfully complete the MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> trials,
and the potential of nex-z to become the first <FONT STYLE="white-space:nowrap">one-time</FONT> treatment for <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and/or ATTRv-PN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: regulatory
agencies&#8217; evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our
product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia&#8217;s product candidates, including nex-z, will not be successfully developed and commercialized;
risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its
licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in
connection with future studies for the same product candidate or Intellia&#8217;s other product candidates; and risks related to Intellia&#8217;s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will
not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking
statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as
discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes
no duty to update this information unless required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contact: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Fredette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jason.fredette@intelliatx.com
</U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 3 of 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ntla-20260302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 6:14:26 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:ntla="http://intelliatx.com/20260302"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://intelliatx.com/20260302"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20260302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20260302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ntla-20260302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 6:14:26 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ntla-20260302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 3/2/2026 6:14:26 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ntla-20260302.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g101756dsp19a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g101756dsp19a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  *$# 1$  A$! Q$!_\0
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M2S)*9!'CYB"N,_F:THQ4KW,Z\Y1M9G4_!C6[[Q!X'AO-1N7N[EIY%,DG7 /
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6:#BE&$KIN2?,_-*R5[ZGL5>L?'G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g101756dsp19b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g101756dsp19b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  7 N0# 1$  A$! Q$!_\0
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MLFSCO@UXUU+QOH-[=ZFT3317/E+Y2;1MVJ?YDUK5BH.R,:,W-795^-/CS5?
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MO7$9DLK_ $XYAN%"LV2,G@A&P1CD$%16>%S"LL1]3QD4I/9K9_U8WS+(\'/
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G3;1+=YH<['([C/-?88:DZ%&%)N]E8_&LTQ<<?CJN*@K*;;L_,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g101756g0301221517365.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g101756g0301221517365.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L ,@# 2(  A$! Q$!_\0
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MRJCJZ>@(#+G![ 1:MH/Q9_;F\7Z.NN^'9_ OP[TZ;S6%PKJS9QN9=X!ED(R
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M=WP>>W9;<F-U *L1@AW2'H>17WI^TG9SW_P"\>VUK!)<7$ND3K'#$A9W)7@
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E ,8X]*** $" "@C(P:6BD @4>@I0 .@HHI@(5R<]Z*6BD!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 02, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001652130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTELLIA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4785571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Erie Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NTLA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d101756d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d101756d8k.htm">d101756d8k.htm</File>
    <File>ntla-20260302.xsd</File>
    <File>ntla-20260302_lab.xml</File>
    <File>ntla-20260302_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d101756d8k.htm": {
   "nsprefix": "ntla",
   "nsuri": "http://intelliatx.com/20260302",
   "dts": {
    "inline": {
     "local": [
      "d101756d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ntla-20260302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ntla-20260302_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ntla-20260302_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-03-02_to_2026-03-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d101756d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-03-02_to_2026-03-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d101756d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://intelliatx.com//20260302/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-26-084309-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-084309-xbrl.zip
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MNG3\"# H_/0K,+2,W]&8'65K<SVS=]E:_05MW9MTVG2>1@$Z*30SZ#7R[-<
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M-Z?GYV?'Y.;GT^OCJ]-/-V<G_2HYNSBIE_B03Y >S4U 9NOTGH*40( 8WG2
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MZ.J4N\Z':RE'ACQ :<$5P8+2T ?,QX(H/DF"F(9,)"J8$@7LJ(93/8/M( 8
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M)P%W.82.; PPFI/:X!\D1JFWB8YC&MH ?@RILA%:E\S%$%R,826023(98&@
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M0GH03B+IU_H!2#<H@)HT<=HKA*(6!B<*@C]HW$X9WB:VX4O;:B(-J$WU6?:
MR'=61#(SL D\N"8KM;J[P]L*L6_0Z2Z0'J%D^RIC&N$<=3+K%>._RH&D'2/7
MJ;XUL>;%Z[:56:^;%T+YH.1"IBS9OI6P#!HC=W=T:.D7\IMP<P0@( Q+N4B)
MV"PY]!G <8-0,8# L68<T]J[TB"(H*LIMT*P@^,O= 2E3#B*E<4!X2>QQJ)
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M=DMS\E!G$Z%1F=]1)I0LC"&)\7&0:(BD!HDKJ*F(.?A\B '<!VQS$4$\9D$
M8W;'#9B*QQ/N:8'-D+-(1",D0.PI,:!U#> AZFS&$MCQ FW80\"RU0<\D%,4
MZR4D_2F^W%ZY7;?6<XR$*;H&46H;W*RR*_;38Z;!0THP5&V=3[L[KT6H)2H=
M&2HAH1 S1NPFS&:K@BQ8OQVF7_"!2IB:I60_='9W4,:C=<JNF7V9A@Y,A1YG
M),K$%G&<L,CCQ@PQR8V;I>8),8[VQ@QGG)G7+\@6;T(7C"YSOO@\%HJ3-L92
M&[F/",9HE:%4J+]UK?S6E6EW;AVJ)[KN1:?K.N2GGHQBX6,4T@*13G%'*?E(
MHF]O]!+BNW$3U(("VU,Z#V6 ?AX_E17>1M5BGH(K3!1GX8 8%<&$C3@4,QW7
MA;5Q;L#GWA8GWMCZF]%9<8RWG%B*=D[)_H^/QP6G4#"?E.*+=;(Q1:=P>.P<
M%D^<D^-LU/9-7[)X#(6*45<*;J1*BD4S<\"VQ%" $&C-O+'Q^]V=K#*N9>ZZ
MCIQ81"AR =^282J5'V<@$',>YLD,,A&&W!<8: )DTQ##;C;-3(%-H1#-^2 :
MT:BC%8"WFE@.\] CT!**NR]C&6PBV66 0?U2^CY3/NR-L)4?V=8_15I'Z/N\
M)\,/J>Z[.^L<=/TI36XD ?-@S[;R/K4>66+[_#RR_,Q"C=5@*!!+!C=*FGR1
MQ-!+)I/ 0CE)%+'69)%N0FGXJ'2T-_@PAYY[B1*:2J0:YAKL+9X>'BZSR"&\
M ZIFHA%.6:DC*4]1&3.5<)[$6++$,338+,Y6I[QH(J <;A^L8P)+H&\NY%T0
M"UT--4F#LX@\J292F2R.^M!;C.Y8_3&,ATH_PM/MJW1B58(-&E&E:RM.EL&_
MNV/PM]&,#22^FZ*M,:C-'?^@T?R&I]OTRF%W!\QO90*QG@5\52,>/E"(NBAA
M[ \P@_S8'W#*B6463)$#.3H^3VB3JR[TFO]&? YSV;KF2J3\[M3\Y."VV>A?
M?<[AB>S]_"Q<QW.[V]W*I<A/V>3C YN$;&8L<H^^E3**/$0J"!$>+"82TH6(
MA<<9CCF$[#4="WR8F],GBF']Q+#<4 (%9H%CCB'T?CY<RQ&G(TDZC\H4+31N
MBJ&?S^OU&#T9A8BU2BQM&SQ HJ@9+80;S 5=J(!.02N0C+,LHYG#3Z9<R'Q.
MHX;,BT5($0C5XQ0FE(R$!UJQ* ZQ9L6"Z4](,Y\V.XIC3P=T\+S'H@>C%9LG
MG=3'266,A@XI.4*74>8<-G,,F@9@E5#.QQ:/D.Y>&C(\#"&^*0\H*-J2,&!3
M\D5;!?<T.2/NLKB*H)$2;8IU)&6>%&?<9!@(3QLWQB6P/)-W@H"<Q]5T8=BX
M[FJ.6#VT&;:E48^4P;XXVY=ATL C3E;BSN])/'$G B/(0D!"P:.15!X3F177
M=J:I^E-D%K@NF\)"^=Q-$02$.E$LP !'>2ZV[,4LF A:T[-K*#L22R5,5XH'
M=FFB+M>2I/6"Q+S+SO0!TE?;JBQ .P1V?DRN:?PBE>RWQ!^%!BZ2WOJ"':_(
M4Y$R>8JGV\T'IWEP[ST^V7AR<IZHK5!F.AOC[S"A$H*L93EMTLC+//:G+G:;
MU?_T,(0SG6"(O,&<$L.%.1;]%V5IFAM82DZ8FC;']0?RP+) GR:8%FP-_+87
MC>MZV0M&F\/^3K;KA#]]+N&;;12_WW9[/3!W#IT+9SEJ@W5S>S?E,7-WMU:R
MTCTCIM<$3U'SO,<64?KIBFE)TR6Q2POZ/<K&9?897%=O_(D'_=IYRX6ZVVKU
M;FKU9OOR<ZZ0,^V;6J.1M5/K'9'QSCO=AMLUW:E4MF<?+=ZJW?3<<O;P)*SK
M-B";6FKVN]7TH9%M?/P>G?6@WUB\^):J8I5=\"L;N#K_]"CKQS_=I9TR%98H
M+LRM2YG=2>'#,U58$XXN[ #10&C;Y!OT35(3.=]J-6OFLJ=VXW[M-^L]!YKM
M>MY^Z9,)N2K@TDY+&UVYS<NK/JI]LJKV4O]B_U+NT=7?3OWJ^6Q9L#6SS?GY
M<(29_(>=O$A= RR&N%ITW4,L ]3B7<'\/-/K#^(#^"+'$5SGH<5EA,62\:.M
M0[C,(.AV;N?6?,MOKK!Z+V]2_X]_05=\]J9]H0/<M3X6?(@EAJF#,!AVAD/A
M8>%#E<(-UL_"-U?7;VZ*EWCAJK?_J52A8+/R!>O?X>6O%EZN\3C-> #7#(]B
M2OZ_A9<-ZF\AO%RSB(WH+-80"D\=4FTKE% Q;LJMJBW*87-UCF[::7S'3O./
M/_\#4$L#!!0    (  U"8ES0?<BMG0\  (TX   1    9#$P,3<U-F1E>#DY
M,BYH=&WM6VMOV\:V_2Y _V&@HD4,2+*EG*3Q(\*1)251CV+[*DI[>[^-R)$T
M#<EA.:0=Y=??M><A40_;L>,4IT!;P+8HSN:>O==>^S',V;O)^U'G[-V@V^]4
M*V>3X60TZ S^MW%\W&R?'=J/N'[H;F!GYY?]W]GYV][EZ'+\NO;;N^%D4&,?
M)K^/!J]KD4Q$8R'D?)&?7*@LYE&MPZH5K.^))!=9YZP__-7??"/#?''RJOE"
M)C7&(SE/($#,\IIYS)6_+>;97":-7*4G1VE^RMSGJ<IS%=M+,Y7D#2V_B)/6
M^O.,QS):GDQD+#2[$#=LK&*.)W5'P[<7KVL9*5GKG)UW!I\7<BIS1CMF9X?G
MG;/#JTY)@9+T-J1OZ;.C3JWS4S+5Z2E)P<9OV\?N.J]98$Q%5C"6&[Y_RSZ,
M>Z]K\]91Z^<7+T.=MHYY\X]T3BLFKVNCR[>7UF9/IO?MYO\VM:=?H7;I@4;O
MIW*XUP\>'^*O*)*<318BXZDH<AEHUDT2520!%K_I=]E(SG*F9JP'3,N 1^R=
MBD*FDA5"[O#M=U#Y???MQ7#RL3]@5PNN!7N^5FR22?R4T.S-Y<5D%5T+F8N&
M3GD@3A)U@VW6.MW)9-SHO3\[I!L[]^WD2:S?Z77?GX^'_;>#.GO/M6[2KRQ8
ML':=M8_:+]E//[QJMUJG;*]/ZK@<--FS"ZY#_N<)NYB,N@=UQEDD>"B3.9M*
ME2XXB"8P"V"'0,4I3Y90*BBT,![+Q+6*\+5*Y!=:%(M0!F"J:B42UWC8G"[V
MQL,/5V,V%XE@^#ZG:SS!^ASZ0&HF6"Z"1:(B-9<"FN4JY$O<8D$3LGS!<_P0
M[&/S0Y.]42HTZ_M9,6?=,(:S=)YQTH(] \ .&/P(U6)U;18+%GB'+AS2Z.(P
MN18ZEW.S$-^198U(GJ81[K;RAA?] ^PX,TMVH;*2G!NHJ%FUDHC/<EYD/&%?
M9! 5L: _G^%JXXN5E$(TX*?9C<P76,@3G2^6F8!A&(^7D9*ATM)]'? LE"I>
M*JQ:+.\'XC.'Q(/F&HO?E00Z!+/VT>EO<#J'*^'V)4N!(H)(KN"+:V%S$#[;
M'<.2Q /.#[0QLLL-=FKLHXJL9.E-"]>MB!CBBPQZA$);R7C2K,@,HD2RX,"-
MMS/3?";RI8$,CR)UPPI-MP?8E$P*07_+%18$,YZBH.=LFBD>(H8?&/VI2HO(
MX*=NC(,8U%R&ZT"\@NHR)-U(J=Y"BAD;?!8!(@G&NIS-9(!]_*(6"1L)@#,+
M$=O-?I-Y6WLS0HZ+/U+X%YX4'-8'M^Y%/0S[%9M9F;[1]AOR:+<@W\4PK$Z!
M3<\F4]B+J8J6B2@RB]RZ<2O/<ZPB=?$TEA=9XEP1 S&&&$22J2B*R3;8$4"Y
M@.9S15^9I^LF^TU0B&8BD.0NAR9#=C^?4MSK5"4:ADR$AO1%IHKY0A5YM9(O
M$%5II@+Z@BP/8DD^&0DQ$=L:!2JS-ZRWN5",T)WR#&0HZ3HTD@;!,(U3S7O[
M>X?<9-N[>D5J%WUM'+0.(.SC<5Z_@5>9C%-%D3Q=EN/V,LC55&2VK&D?FX3S
MHHX'4WP97^%>-=4BN[8\"DB^S7@HV+]8!-=DEO:PO03(LK:629!YULBQKZF,
M9%9,96)CT4<S>>(&_!X:M0S25A&[WK1)&;$P3G?N62$$",A5H*)&*&:2N"/E
MA2:E@PQVP:U-9@SLTATED]OX*Y8^@:PI:<?Z]Y/V'N.;#< D40&C.48+68Q$
M"W"2LK"HM63$IRHCR,)#@*^N5ROS0H:& DD7O5!9WL#&8J;Q$]D%]A \MS$V
M8P*I&H$4[G=,YOTH0@=W_,*NX: 4ME)AR>F4MEQNI_O$9VBOG?<W"0/TEG.(
MLX_DT\1T-! K-"7XD@%1DH14,Y@4O9;H7644G H\MEJ!M526DBU$N(>D.*B!
MRCX&%C#6@E8VNUYS'8"P,^Q,YYQPY])%O@#([&KQAPB,GV<9MW_\%.6G[1<_
M,E>;Y A2$JF!8I% H>::[T$[(IGSN4?05M6PP3MU)L!3*)J!/\ K%U012:I6
M$U^I9&).^05[0,HMH&1F+%<JJK"-3X*(062&8(%+%")E<J5-7-ME&X'S4+S^
M967&6D58DU<K@&FH8BQ&;@Q5,8U$8PJSXE,:0=>I:E""I_T2HQ@[ ^=189G;
MX)/R+ ^LJUV1  >N\S^2C/HL8^ I6K)6O7UTM 6IKRT,5D8B7DDSB 3\1!*F
MR&NY3]<."YI-N:NNN>$@!!72G*,74V%NHK:1B<A 'A4W-*L[UC#E."*?PFK9
M1)U<1/DCU??:4ZRMS<[:)RV+K4!0V<(917\DV(L7+*;<.%L%OS4I1:1UC8WQ
MF"I_W$:Q;Y-$&8C/+GJ3HY>M]JN7[>,#<)HM*=FUA#E<._VQXP/)Y=^YNCX[
M_-AI6C!2 YQ^;;/-RG!\M=6ST_2F>SX:L-Y@-/IPU>T-+]Z^KAW5S.>K;K_O
M/_\V[$_>O:ZUCHY^K+'SRW%_,#;7G1+V2J-W.1IUKSX,3OP?=T)_.T[VC 6,
M@F/_1]^K\:+U(SK<PTE__<VO;JW=^%IA?^.F@'^]\M?Q8VR_'/O-I."SQA29
MY%,#O(ER]H1?4W)YV&8Z6XK!0;7.%42S%B'G>5FK+>6=A[R?=N\C65M#*>DH
M.?_<1&RMMX8?Y& W4COL#W_%)3=9,\8CT2EX=1F)37(3\0ZWT:62=:8"$(=U
MHAN^U#5BRI0& ^]@R>'_P9#/:UZNF?R=_'!L_MM"D]M';W Q&8S_ZV9_G<?4
M.$3D[.$\7JU\$Y&_W&;Q[>YEIP??[&28:;&O&U<7!\V]A*X]H^N\")>&-<'D
MJ.#F1'>@O5#.)#93$HDJF\O,)&9M!B*F62TM0@56Q-4*J4>3%6J#]C&ZUVR;
MJEO?@:H?XW%+ZB]_;K>?_WQ0=V.":N4!I+Z_PGCU)! ^[W2G:!3-\([F=_;7
M?=NT>E^0W=PV:26[8_SW\HFTI>><^V+A @U9=+]3KC+(;Z!<IQ+5N\5.Z Y[
M7!]OCNE6<SGT[Q89U V9J8TRG3S5L H%.,C4MN(SF>G<J5&MW*&(2D2#:N95
MP[/J2<RT;6,J9B+NX F'8ZN*)@D/\;2OF%^4H_XKVNDR'(CGRG,JM%94?/OA
MQ=FP \EGA\..M;WI_ 1ZF= UD[8XW+"',0?UL8+HC9IG;;N@\B0K_+;*OKXU
M_4'=N=&VZ,<,QDD);\BZF=506P5"6]IV"53JGM=:=TDASSFUL3=NG,LW9[XK
MUHJL?0,:_VB")S**$*EY:*22>2/BVL":? R/%Z:1>[ [[739,"D-HMEEEH*G
MW>P8CQJ_[TY8WSB<NY91Q0^:7QOVWQ1<EO?LLD]#:2]U0!@5N+%'':,F)B_U
MGC3/)_S!QBJ-W<P1OL2](@O@1_EERXS8'HVYZ )G,9*,;" TYB)GH41VH@%O
M?5L@VY47(&7;T01],B$U%H3P#!^O-HX6W&G$72<F3\KP^X]$]IU0/C5KWW$6
M4ZUL'L;8\L@?Q_A@:*"U1TGP3:<S[/&',QNCL=5$S:&.-$;\&:ZB4L&@DT8\
MIB)*A4*^MT#0I( @/%$!H*N5Z=(CRBM0!A1=6R4<E'!!0:BZ%NND06-A$FSB
M70=4$J'("NI6>6,@(W1%*27XBL\TR0+CBOH:&%S&?G(B<E?-08(_HUB9DA2'
M-E-H993Q-6FF5([\5&B[>;?3)AL)GB6VGN(YP/YQIR7Y:%G2CM7HK +W_'M]
MTU]6"[VQ1S*-D5*?:%<?<N048^O[CC>?)%(F=EA/H_I,V-Z?&@&.7M,?@[A#
MHT;D--0K#?T@'I:_\_33"?+WK);9I.N^[:W1CB\/JA6"L)N%QN!=-XVECZBN
M3%[_( !1.UT;K4?$8V&BHAL8;FT='[\PX:0%NWTG?@9<9U/P%I7U"8 5R5CF
M)MO5";[&2E :;41$G45I>2;F5"1!9GF3)FI1+THQLV-#BH$@-VJ6UIQ8X)N.
MJEZMY"J"">U\M+[JNNI,%\'J2(6'US1Y-H&%34JHL HZ%"SSC,>VJME[3(KK
MSN@F%7E_/$.*4.P3LG%"V8GHL=$^.FH=E(==IC)PPUL$KAVX[INW4H/_SWCH
M[SX>:O\S'OH;C8?H=.:QAQSL:<XXB(J>X%34]3Z.PNR Z=NZH"WB<FPZ*TRE
M8T_&Q=;K)X\^533*@\K]&=VZC5^5_[?W\X_NYA]A'VK+O8F:=PU3GN9TJ6LJ
MYSN2,,MWZQ%S]NCG+Q"#F*;;5PD6-4#F"\Q5<B7+^\P+F\^*G(YU[-F-S:#X
MJ(LIG3>2+WBUDA3Q%(#'W9G4G^Q=]&:4.4,U\#8S@T 546AK3H)^88)(HW\S
MX1'*V0Q": B:V2K:I6N$#XU%73M)!YY4\<(82)PR*9<5J'4!SL4=AO+US&UZ
MWE/,G&P>;:(I026OG3U7QW>V5RWQPPRQD\S+W% >5?KC,=B 7D%!$4*-/^R4
MA#+$-QLG9B8$3K>T+DDPL6KIR+:Y=7<<;AYE^Y;$R*>CX!Q"-SBKW'9DXL]"
M9@Y@[KVG:N5N]6[5J\R6-.V^)HZRLQ K;G-T<VI[%'C)0H<:1X0P\Z/>4MU<
M?FWB/L/1VUE19)PZ%9M$YG8NPIWF3H2GU8H%3&E#.X\O,:09? 5V[A"3,;BC
M=YN^A<5^2E.1#"O,"2K<<\IVG@(ST>L0"YF%9N:QW"]BS\H=_<QW%.$+F?KW
M1+Q8N6DKJ%JM1!(%FO8O&ME/2(-['E7.#ZZD7B^^S1Q8)+-[#;*) O=&F6$,
M:M@SL8*-AS( LG.M[/.4!JEFHE<B-R]3)C1W2A+W)H4QDKO%R_+S3LUCL8LX
M>OR.X6UD[:+SU!CDJQPGS<LRVS,KO=E=T/LXU,T\>*QE# 06IX& ?^<0&]D?
M*O:\A9M16Z']J8Q]RVS-([?P:[U,@7%*I_^4@9$,3,UEHGS&D(!!XN5LL1ML
MMZ6/4I9PW?CZO:"MM%"MK/,">D1AZPGMG$]51TX#6]?OC0F%;ZRFONV#W!W-
M8J5S_R(/3Q*K)>V4W/>&VNM[BXW64>,_Y4KLSP(A*C*0U",D_<]J3([&] :Z
MXG>ULO:>C:15E64<5W^ U_8:P=[KT][JI;32U($D#CZ[\\/R7+@;11O9<7]E
M0Z/'U3&FC;R9HP=S@U5Y-5HIDI"V\XDF>0FP4EB>+M+0'G)(O?',(HGLPTP"
M-'5%Q&_N'&I]CW^N\ .C_[][:4D'=<-.CZ(ER$\8'?3\!8/F7[@F&,.\ NW5
M7;M\DO[N5R2D]6O-=?=R/9AL[-.B?=79OZ!G,%DD[C5[_=WUNVL*>/<_R_EV
M_W_L_$'.:,Z<,_Z].66@@<+'SC\CJ;__2.KY?]5("B1SV?\=%\T_0_Q_4$L#
M!!0    (  U"8EQ("7&9.0,  $0+   1    ;G1L82TR,#(V,#,P,BYX<V2]
M5N]OTSP0_H[$_W#D$T@D;MJ728O6(6!,FC0&*@/Q#;G)M;-P[& [6_O?OV<G
MZ;)V+=V&Z)>ZOGONGOOI'KU=E!*NT5BAU3A*DT$$J')="#4?1[6-N<V%B-X>
M/W]V]"*.X>3T[ )BN'*NLAEC-S<W23$3RFI9.[)@DUR7#.*XT_]P^0V^-]8S
MF*!$;A%*-'.$][60138<# \&:3I,1GV40>[-0<$=9C!B0^;UX"!+_\OH^\LG
M^,BM0Z/@4I381^IJ:<3\RL'+_!4$T(E6"J7$)9P*Q54NN(2O'=_7<*;R!-Y)
M"1,/LT32HKG&(FFM+FR1V?P*2_[\&0!E2]E,D<FZ'$<^#6T6%E,C$VWFK'"&
MN66%C)1BTD(C\J@'_3-N T-E\!*[ LZXG090)_'I>=/WXB1?:0OE*'[!W2)4
M)V1\-!CVU L4*^U R&*>S/4U(\&Z:2\7]X<P' Q&Y,TZRC+V(%*H7SL07CRE
MON@[V8#<C (@/3P\9$&Z1JEP=R-HK;]AC3!H<^>,F-8.3[4I3W#&:TFH6OVN
MN10S@470HB8M4;D[.G<U'*?^=1>\1%OQ'!^0:&JF^Z(BHBG[\>G\:^BSZ-@#
M $+KB;+2QD'3@><Z#W.Q(YG^5]S5(/97<3J,1VE"QB)0&YQW%!#8DXETI7T4
MD55?[$W$;NM??XC]89OW^[O^T1E8'V8?_Z&//SW8*_Z-9? 7F&AU\50RO8WV
M^)HH+O)F837'_>MRBWQ2;W8[P>=AM^/U)=)Z#3ZY4MH%1WTFO*J$FNGVBBY]
M$V==)T]P!F%Y9=SD1DO<O>)8972%Q@E:\+?#T!BX,C@;1W[/Q]V>^2GY-*$]
MTZEL.+@[7E[,"(+R_)9>AW7">?"Y%X.7TTO)Y<JT;X=Q9"GOLC>>_SC<RN!#
MPR6(I=T>RK8]ZB\]K0<'[_U<D@;XP[?)V;;78?4\,,<76NERV5 \T7GMWY_N
M^YTJ/BHBMCRCOC)E(!6!H'=D0NH_]U)?4>Q(%DA_VD1HWG3@/_2?KK/0/W)5
M0&,.>O:.V+J1=?NUQ>*S.@[GG,N\EJN4M^!68Q=PO5C[(V^9;<>UMUVYNB%F
MZU/<WO2GO;EJM@W]_!]02P,$%     @ #4)B7*1WWX!Y!@  MT8  !4   !N
M=&QA+3(P,C8P,S R7VQA8BYX;6S-G&UOVS80Q]\7Z'>X>6\VH+)C9RM0HVF1
M.4EA+$]HW&W8,!2RQ-C$9-(@Y=C^]B/UT,@Q)5/AJ<J+-HIT][_[*[]3&%GV
M^X^;100/1$C*V4FGWSWJ &$!#RF;G716TO-E0&D'9.RST(\X(R>=+9&=CQ]>
MOWK_@^?!V<7X&CR8Q_%2#GN]]7K=#>\IDSQ:Q4I2=@.^Z('GY?&CR1?X(RTW
MA,\D(KXDL"!B1N"W%8W"X>!H\/:HWQ]TCXM9@OA:#D(_)D,X[@UZ.@[>#ON_
M#-77VRLX]V5,!(,)79!B)E]N!9W-8_@I^!F2I#/.&(DBLH4+RGP64#^"N[S?
M-S!F01=.HP@^ZS2IFI1$/)"PFZE&E/TWU/]-=>OP^A6 .H=,)OM..OI,9"=B
M,Q51EXN9ZO7HN)>G=!XS-GLIZ^,DH?_NW;M><K08+:DI5HGW>W]=7=X%<[+P
M/77NU<\JR,I(.I3)_DL>)&?0HD$HC=#?>7F8IW=Y_8%WW.]N9-CYH MF9\>?
MDNA2;4'B82AX1"H*Z\-)]4X6'V^7*IYL8L)"DBE_T^9!%C47Y#Y5U>0EDI($
MW1E_Z(6$:D!^U1N>WM =_JB^^3KB"O;3J8R%'\2[]2)]BKC(=R8F3CJ&I-YN
M0SKN5 0[6KX(<AVU><!_%M$+N/JY+6,O4<S3[P5?&+O(RG'#P:_1-#*VJ4E2
M6WJV"?.^W!WRF@H5C0DB^4HHO.K\:!,_'Q)E^"?7_O=][['V2VE574(DN:S;
MKQN2IPN%N?H77T3^S!;))TDM(6ENG1L.NB!I$$)"\ILR:&EG(!MHM BD;;=N
M.)ZSF,;;D2HC_&BL+L";W\G6%LN2Y);PK+;"*X)<<*T01,(VK0!9"4AJ@"KB
M#'"#K1=!KM^_&])G/%CIN9FH[FU)WLUI"6!CXWS_F NN^SI(E.;"H)6=T<1O
MLTBD9:\X&-X207EXSL(S]==,71Z?)+<,IMD*KPC"0-4@B,UL6@)4#=!%T/!M
MH'4CQ];]8RP6/I,9U8MD%E_["VNBS;FM+A5*C/#R&/>%@DD/=YWP6 %T":15
M0A-]&Q8)ULUC@#QF 1=++I);)7>Q&IP17ZE%RG;$PYI<'Y!J%7,[F]PZQ7T(
M+.1Q9V*G("05(2L)NB;2D'P'7X:9>;XYC"&ZH!&Y7BVF1-2;F&)>J^-A,,#-
MQ]W!?ZJ%2[E6AU0>"6CL?@WT6C6- >K$WXQ#M5BB]S2].?X<:DM%6D7XD#5N
M$>P.=Z4P+NFJ%.S6PN6^42N&(7B&'XR1. U#94!F7RXI(_UZXV 4:'44JBSQ
M X'N(U JBHM_IO\FWP!="6X8UCJF,1L&])_AI1GT!Z[H#UX<^@-;] =-H#_X
M?NA/UKPQ])%L6*-?Z041_9':O!$3OF;/ K^8_A*P-]@Q0?\8AH;\4\F&@-=E
M@ O0A7!AQS90A;J="T3,D[^';\2MX ^4!35OZY1IO 3@RXR9J'\2BX:^4;<A
M_M,;&PJ=O!KN$#1BI6H2:OA!'(=;+F,_^ILNZ]_C-"N\A%$PFS(-PDXDVA@8
M5!L:@K02J%*8]RV;LU$U -9>')\!U 8%\>L OYO3UA. IL;Y_C&GY__V=)#
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MGP  #@              @ $     9#$P,3<U-F0X:RYH=&U02P$"% ,4
M"  -0F)<R@&\M_P)  !V(P  $               @ '>'0  9#$P,3<U-F1E
M>#4Q+FAT;5!+ 0(4 Q0    (  U"8EP.Y3S_! D  /\C   1
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E,#(V,#,P,E]P<F4N>&UL4$L%!@     '  < O0$   ]0      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d101756d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ntla-20260302.xsd" xlink:type="simple"/>
    <context id="duration_2026-03-02_to_2026-03-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
        </entity>
        <period>
            <startDate>2026-03-02</startDate>
            <endDate>2026-03-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-331">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-03-02_to_2026-03-02"
      id="Hidden_dei_EntityCentralIndexKey">0001652130</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-342">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-343">2026-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-344">INTELLIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-345">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-346">001-37766</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-347">36-4785571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-348">40 Erie Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-349">Suite 130</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-350">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-351">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-352">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-353">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-354">285-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-355">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-356">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-357">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-358">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-359">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-360">NTLA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-361">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-03-02_to_2026-03-02" id="ixv-362">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
